Name change to Talphera reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings
Talphera will begin trading on Nasdaq.
Use of CRRT increased during COVID and remained at these higher utilization levels
Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT.
Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter.
HAYWARD, Calif., Oct. 26, 2023 /PRNewswire/ AcelRx Pharmaceuticals, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in.
/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of.